Details of the Drug
General Information of Drug (ID: DM742IJ)
Drug Name |
2-Piperazin-1-yl-benzonitrile
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(2-Cyanophenyl)piperazine; 111373-03-6; 2-(piperazin-1-yl)benzonitrile; 2-piperazin-1-ylbenzonitrile; 2-(1-Piperazino)benzonitrile; Benzonitrile, 2-(1-piperazinyl)-; 2-Piperazin-1-yl-benzonitrile; 1-(2-Cyanophenyl)-piperazine; 2-(1-piperazinyl)benzonitrile; CHEMBL275943; 2-piperazinylbenzenecarbonitrile; PubChem9347; 2-Piperazinobenzonitrile; AC1MC4BA; AC1Q4R0F; (2-cyano-phenyl)-piperazine; KSC491G1H; SCHEMBL233169; 1-(2-cyanophenyl) piperazine; ACMC-20999f; 1-(2-cyano phenyl) piperazine; Jsp000853
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 187.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||